Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Real Time Quote from BATS)

$20.22 USD

20.22
212,649

-0.22 (-1.08%)

Updated Sep 18, 2024 01:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New Strong Buy Stocks for October 11th

by Zacks Equity Research

PBF, PRAX, CPRX, MFA and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 11, 2023.

Humana (HUM) Boosts Healthcare Choices for MA Members in Denver

by Zacks Equity Research

Humana (HUM) enters into a deal with Denver Health to expand its local provider network across the Denver area as well as offer greater care access to its Medicare Advantage members of the region.

Tirthankar Chakraborty headshot

4 Stocks That Exhibit Solid Earnings Acceleration

by Tirthankar Chakraborty

Invest in stocks like Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Inari Medical (NARI) and Kyndryl Holdings (KD) for superb earnings acceleration.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised

by Zacks Equity Research

Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.

Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of 32% and 7.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $12.66, moving -0.78% from the previous trading session.

Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $13.53, marking a +1.42% move from the previous day.

Catalyst Pharmaceutical (CPRX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Catalyst Pharmaceutical (CPRX) closed at $13.15 in the latest trading session, marking a +0.15% move from the prior day.

Is the Options Market Predicting a Spike in Catalyst Pharmaceuticals (CPRX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately.

Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera

by Zacks Equity Research

Catalyst (CPRX) announces entering into a definitive agreement to acquire licensing rights in North America to Santhera's DMD treatment candidate, vamorolone, which is currently under FDA review.

Catalyst (CPRX) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Catalyst (CPRX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $11.83, marking a +1.37% move from the previous day.

Catalyst (CPRX) Down 16.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JPSE

Wall Street Analysts See Catalyst (CPRX) as a Buy: Should You Invest?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks.com featured highlights include Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum

by Zacks Equity Research

Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum are part of the Zacks Screen of the Week article.

Implied Volatility Surging for Catalyst Pharmaceuticals (CPRX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately.

Tirthankar Chakraborty headshot

5 Stocks to Keep a Tab on for Solid Earnings Acceleration

by Tirthankar Chakraborty

Notable companies to have witnessed earnings acceleration as of now are Catalyst Pharmaceuticals (CPRX), Warby Parker (WRBY), MakeMyTrip (MMYT), Brookfield Renewable Partners (BEP) & Century Aluminum (CENX).

Should You Invest in Catalyst (CPRX) Based on Bullish Wall Street Views?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Catalyst's (CPRX) Q1 Earnings Lag, Sales Boost Revenues

by Zacks Equity Research

Catalyst (CPRX) reports mixed results for the first quarter, wherein earnings miss and revenues beat estimates. Fycompa sales boost revenues. The company maintains revenue guidance. The stock surges 3%.

Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of -13.33% and 2.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Stock Moves -0.12%: What You Should Know

by Zacks Equity Research

Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $16.60, moving -0.12% from the previous trading session.

Catalyst (CPRX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Catalyst's (CPRX) revenues in the first quarter of 2023 are expected to have been driven by Firdapse sales. Updates on generic competition and the commercial launch of Fycompa are expected.